to scale back the risk of main cardiovascular situations like Loss of life, coronary heart attack, or stroke in Older people with recognised heart disease and with both obesity or overweight.Nstarts promoting its rival drug in Europe and The us. The Danish drugmaker is Doing work to influence European governments and insurers to reimburse the drug,